American investors love drama. So it is no surprise that Theranos is causing a stir. Just two months ago this blood diagnostics company — created a decade ago by Stanford dropout Elizabeth Holmes — was an investor darling valued at $9bn. Now, however, it faces allegations that its testing techniques were not as novel as claimed, and the company has become a lightning rod for wider investor concerns about the sky-high valuations now seen in Silicon Valley.
美國投資者喜歡戲劇性。因此，Theranos引起騷動並不令人意外。就在兩個月前，這家血液診斷公司——10年前由史丹佛大學(Stanford)輟學生伊麗莎白•霍爾梅斯(Elizabeth Holmes)成立——還受到投資者的青睞，估值高達90億美元。然而，如今該公司面臨指控：其檢測技術並不像該公司聲稱的那樣新穎，同時該公司成了投資者對如今矽谷天價估值的更廣泛擔憂的典型對象。
您已閱讀10%（646字），剩餘90%（5709字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。